Papillomavirus Prophylactic Vaccines: Established Successes, New Approaches

Campo, M. Saveria; Roden, Richard B.S.

doi:10.1128/jvi.01927-09

Cited by 55 publications

(45 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The quadrivalent vaccines present some limitations: they are effective primarily against some HPV types, are expensive to produce, and need a cold chain. New vaccines targeting the minor capsid protein L2 have been proposed (Campo and Roden, 2010).…”

Section: Discussionmentioning

confidence: 99%

Human papillomavirus infection in Brazilian women with normal cervical cytology

Miranda¹,

Pitol²,

Moran³

et al. 2012

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We examined the prevalence of human papillomavirus (HPV) infection in a sample of Brazilian women presenting normal cervical cytology. Possible interactions between patient characteristics and HPV infection were analyzed in order to provide background data to improve cervical cancer screening and prophylaxis. Cervical samples of 399 women, received for routine evaluation in the Health Department of Ouro Preto, MG, Brazil, were subjected to HPV-DNA testing by PCR with MY09/11 primers. HPV-positive specimens were typed by RFLP. A structured epidemiological questionnaire was administered to each woman. HPV prevalence among these cytologically normal women HPV infection in women with normal cervical cytology was 11%. Twelve viral types were detected, the most common being . HPV was more prevalent in younger women; high-risk viral types were detected in 61% of the infected women and 27% of the infected women had multiple HPV infections. Significant associations of HPV infection were found with age, literacy, residence, marital status, lifetime number of sexual partners, and parity. We detected a great diversity of HPV types in women with normal cytology. This kind of information about local populations is useful for HPV prevention and vaccination strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Human papillomavirus infection in Brazilian women with normal cervical cytology

Miranda¹,

Pitol²,

Moran³

et al. 2012

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…HPV does not infect any laboratory animals because of the strict species-specific restrictions of these viruses. Therefore, it is not possible to directly test HPV vaccines against HPV infections experimentally [23,24]. CRPV infection shares many HPV disease properties including persistent infections that can progress to cancer.…”

Section: Introductionmentioning

confidence: 99%

Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits

Budgeon

Balogh

et al. 2014

Trials in Vaccinology

View full text Add to dashboard Cite

Long peptide immunization is a promising strategy to clear established tumors. In the current study, we investigated the therapeutic effect of a naturally existing long peptide that contained two HLA-A2.1 restricted epitopes (CRPVE1/149-157 and CRPVE1/161-169) from cottontail rabbit papillomavirus (CRPV) E1 using our CRPV/HLA-A2.1 transgenic rabbit model. A universal Tetanus Toxin helper motif (TT helper) was tagged at either the N-terminus or the carboxyl-terminus of this long peptide and designated as TT-E1 peptide and E1 peptide-TT respectively. Four groups of HLA-A2.1 transgenic rabbits were infected with wild type CRPV DNA. Three weeks post-infection, the rabbits were immunized four times with TT-E1 peptide, E1peptide only, E1 peptide -TT or TT-control peptide with two-week intervals between immunizations. Tumor outgrowth was monitored and recorded weekly. After the third booster immunization, tumors on two of the four E1 peptide-TT immunized rabbits began to shrink. One animal from this group was free of tumors at the termination of the study. The mean papilloma size of E1 peptide-TT immunized rabbits was significantly smaller when compared with that of the three other groups (P<0.05, one way ANOVA analysis). It is interesting that E1 peptide-TT vaccination not only stimulated stronger T cell mediate immune responses but also stronger antibody generations. We conclude that the location of a TT helper motif tagged at the long peptide vaccine is critical for the outcome of therapeutic responses to persistent tumors in our HLA-A2.1 transgenic rabbit model.

show abstract

“…Skin papillomas are usually difficult to resolve and no effective therapeutic vaccine is available for clinical use to date [15, 37-39]. It is intriguing that epitopes CRPVE1/303-311 and 149-157 showed potential therapeutic effects in HLA-A2.1 transgenic rabbits.…”

Section: Discussionmentioning

confidence: 99%